<p>Secukinumab is a human interleukin-17A antagonist indicated for the treatment of:</p>

<ul>
	<li>Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy</li>
	<li>Adults with active psoriatic arthritis (PsA)</li>
	<li>Adults with active ankylosing spondylitis (AS)</li>
</ul>